- $136.04m
- $29.19m
- $33.03m
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte Announces Retirement of Board Member
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
Brief: Maxcyte Announces Streamlined Operations And Raises 2024 Revenue Guidance
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Third Quarter 2024 Financial Results
MaxCyte Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: MaxCyte Q3 Revenue USD 8.2 Million Vs. IBES Estimate USD 7.37 Million
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
MaxCyte Inc expected to post a loss of 12 cents a share - Earnings Preview
RCS - MaxCyte, Inc. - Upcoming Investor Conferences
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing